Development and validation of an immunoassay for quantification of NCAM-1 in human plasma

被引:2
|
作者
Guven, Arcan [1 ]
Gray, Kayleigh [1 ]
Peng, Kuan-Wei [1 ]
Klotz, Allison [1 ]
Kellogg, Mark D. [1 ,2 ,3 ]
Narain, Niven R. [1 ]
Kiebish, Michael A. [1 ]
机构
[1] BERG, 500 Old Connecticut Path, Framingham, MA 01701 USA
[2] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA
[3] Boston Childrens Hosp, Dept Lab Med, 300 Longwood Ave, Boston, MA 02115 USA
关键词
NCAM-1; Biomarker; Assay development; Assay validation; Immunoassay; Ligand binding assay; NK CELL; CD56; LEUKEMIA; ANTIGEN; EXPRESSION;
D O I
10.1016/j.jpba.2021.113981
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Background: Neural Cell Adhesion Molecule 1 (NCAM-1), a multifunctional member of the immunoglobulin superfamily, is expressed on the surface of neurons, glia, skeletal muscle, and natural killer cells. NCAM-1 has been implicated as having a role in cell-cell adhesion, involved in development of the nervous system, and for cells involved in the expansion of T cells and dendritic cells which play an important role in immune surveillance. Sensitive and specific methods to quantify non-surface bound NCAM-1 are not available. Method: A sandwich ligand binding assay was developed for quantification of NCAM-1 in plasma and validated using an electro-chemiluminescent (ECL) technology. Results: The data presented here demonstrated that the validated method met all prespecified criteria for precision, linearity, and accuracy in the range of 62.5 ng/mL to 4000.0 ng/mL, the range believed to be most relevant for plasma. The bioanalytical validation of the assay established the inter-assay coefficient of variation <8 % for calibration points, <2 % for high quality control (HQC), <8 % for medium quality control (MQC) and <19 % for low quality control (LQC) samples. Purified NCAM-1 spike-recovery experiment in plasma was used to determine assay accuracy; nominal concentrations (%) of NCAM-1 ranged from 91 % to 112 % for high and low spike level, respectively. Assay performance was subsequently evaluated for parallelism, selectivity, interference, and stability. Conclusion: NCAM-1 assay has been developed and validated in human plasma and met all assay validation parameters pre-determined during development. Clinical testing of human plasma samples indicated that NCAM-1 does not seem to be influenced by age and was slightly influenced by gender. NCAM-1 assay has potential to be used as a biomarker assay once the assay is subjected to appropriate clinical assessment and diagnostic thresholds are established. (C) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Development and validation of a novel multiplex immunoassay for the simultaneous quantification of food allergen proteins
    Oliver, M.
    Kuklinska-Pijanka, A.
    Bermingham, M.
    Chapman, M.
    Hindley, J.
    ALLERGY, 2017, 72 : 333 - 333
  • [32] Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma
    Perez-Grijalba, Virginia
    Fandos, Noelia
    Canudas, Jesus
    Insua, Daniel
    Casabona, Diego
    Lacosta, Ana M.
    Montanes, Maria
    Pesini, Pedro
    Sarasa, Manuel
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (02) : 751 - 762
  • [33] Development of an Immunoassay for Quantification of Soluble Human CD40L (CD154) in Plasma Samples
    Pedersen, Kathrine
    Laursen, Nick Stub
    Hansen, Annette Gudmann
    Palarasah, Yaseelan
    Thiel, Steffen
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1176 - 1176
  • [34] Development of a fluorescence immunoassay for measurement of paclitaxel in human plasma
    Sheikh, SH
    Abela, BA
    Mulchandani, A
    ANALYTICAL BIOCHEMISTRY, 2000, 283 (01) : 33 - 38
  • [35] Development and validation of a LC-MS/MS method for the quantification of the regioisomers of dihydroxybutylether in human plasma
    Yuan, Bo
    Li, Li
    Fu, Yao
    Jin, Yi
    Guo, Lixin
    Xu, Haiyan
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 911 : 27 - 33
  • [36] Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma
    Damen, Carola W. N.
    de Groot, Els R.
    Heij, Marianne
    Boss, David S.
    Schellens, Jan H. M.
    Rosing, Hilde
    Beijnen, Jos H.
    Aarden, Lucien A.
    ANALYTICAL BIOCHEMISTRY, 2009, 391 (02) : 114 - 120
  • [37] Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of adefovir in human plasma
    Chen, XY
    Liu, D
    Zhu, L
    Zhong, DF
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2005, 19 (13) : 1893 - 1898
  • [38] Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma
    Hailat, Mohammad
    Al-Ani, Israa
    Hamad, Mohammed
    Zakareia, Zainab
    Abu Dayyih, Wael
    MOLECULES, 2021, 26 (13):
  • [39] Development and validation of a nonisotopic immunoassay for the detection of LSD in human urine
    Cassells, NP
    Craston, DH
    Hand, CW
    Baldwin, D
    JOURNAL OF ANALYTICAL TOXICOLOGY, 1996, 20 (06) : 409 - 415
  • [40] Validation of a newly developed immunoassay for TDP-43 in human plasma
    Matsuura, Sayo
    Tatebe, Harutsugu
    Higuchi, Makoto
    Tokuda, Takahiko
    HELIYON, 2024, 10 (02)